@entity6239 and @entity4235 in the management of XXXX .

@entity1 @entity11060 @entity4235 @entity1910 @entity12737 @entity6239 @entity699 @entity111 @entity16663 @entity701 @entity652
Fifteen @entity1 with endogenous @entity699 were treated with @entity4235 and/or @entity6239 . The duration of the therapy varied from 19 up to 365 days. In @entity1 with @entity699 , @entity4235 (0.5-2.5 g/day) and @entity6239 (0.5-1.5 g/day) seemed equally effective in reducing the @entity701 excretion (54 +/- 9 vs 40 +/- 7%). The majority of these @entity1 also showed a clinical improvement. In 1 @entity1 with @entity652 , @entity4235 induced a remission. In another @entity1 with @entity16663 , and in 2 with the @entity11060 , the @entity701 excretion was significantly reduced by the combination of @entity4235 and @entity6239 but no obvious clinical improvement was observed. Side effects i.e. @entity1910 and @entity111 attributed to @entity6239 was seen in 3 @entity1 which necessitated the omission of treatment in 2. On @entity4235 a moderate @entity12737 was observed in 1 @entity1 . In conclusion both @entity4235 and @entity6239 were useful as adjunctive therapy in @entity699 .
